2020 U.S. Infectious Disease Market - Hospitals, Labs, Blood Banks & POC Locations - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 31, 2020--
The “2020 U.S. Infectious Disease Market: Supplier Shares and Sales Segment Forecasts - Hospitals, Labs, Blood Banks, POC Locations” report has been added to ResearchAndMarkets.com’s offering.
The author’s new report is a strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key US market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic Technologies; forecasts volume and sales for over 100 infectious disease tests performed in hospitals, blood banks, commercial laboratories, physician offices, public health, ER, OR, ICU, cancer clinics, ambulatory care centers, surgery centers, nursing homes, and birth centers; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.
Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic Technologies; and a wider availability of immunosuppressive drugs.
Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection Technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Opportunities and Strategic Recommendations
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Market Segmentation Analysis
Current and Emerging Products
The companies analyzed in the report include:
For more information about this report visit https://www.researchandmarkets.com/r/hpr4n6
View source version on businesswire.com:https://www.businesswire.com/news/home/20200131005392/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/31/2020 10:42 AM/DISC: 01/31/2020 10:42 AM